Through strategic investment in biopharmaceutical, device and diagnostic research, development and manufacturing, New York fuels the creation of cutting-edge healthcare solutions. New York is growing its life science industry through a broad range of economic development programs and public-private partnerships, supported by the state’s award-winning research talent. And through its $620 million Life Science Initiative, New York is expanding the state’s ability to commercialize research and spurring the growth of a world-class life science research cluster.
We’ve gathered highlights of the many New York State programs and investments that are creating one of the world’s most innovative life science ecosystems – in a convenient one-sheet reference guide that you can download and share.
New York’s statewide Cell and Gene Therapy (CGT) Initiative includes a $150 million investment in the development of the New York BioGenesis Park to be located on Long Island (pictured), which will transform CGT research, development and manufacturing statewide; and a $30 million investment to expand the CGT research and manufacturing facility at Roswell Park Comprehensive Cancer Center in Buffalo.
New York State is reshoring preclinical drug development with the “Lab of the Future.” The lab will enable biopharma companies to leverage use of artificial intelligence (AI), machine learning (ML) and robotics to offer improved speed, precision and cost-efficiency to preclinical drug development with this next-generation pilot lab facility.
IndieBio New York is a startup development program backed by global venture fund, SOSV, which invests in early-stage life science startups that are tackling the world's most pressing problems in human and planetary health. IndieBio New York promotes innovation by offering companies a dedicated four-month educational program, investment, free lab space, and the opportunity to become part of New York's fast-growing life science ecosystem.
in the nation for R&D spend by publicly traded life science companies in the state
in the U.S. for NIH funding – approximately $3.6B
in the nation for highest number of bioscience patents issued
This strategic plan describes investment opportunities designed to make New York the leading destination for Life Science development.
The Annual Report details the operations and accomplishments of New York State’s Life Science Initiative during 2024.
New York BioGenesis Park, located on Long Island, will transform the research, development, and commercialization of life-saving therapies statewide.
For press inquiries, please contact [email protected]
Phone (631) 400-4193
Email 
